Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Nordic Society for Pediatric Hematology and Oncology | OTHER |
| European Organisation for Research and Treatment of Cancer - EORTC | NETWORK |
| Dana-Farber Cancer Institute | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Development of a second neoplasm (SMN) during or after therapy for childhood acute lymphoblastic leukemia (ALL) is a rare event generally associated with a poor prognosis. In this international study we analyze subtypes of SMN in relation to their initial leukemia characteristics and treatment, and their subsequent overall survival.
To explore epidemiology, potential risk factors and survival rates of second cancers occurring as the first event in childhood acute lymphoblastic leukemia the involved study groups will collect anonymous data on all such cases diagnosed within the last decades to form a common database with predefined variables comprising the clinical, biological, and cytogenetic characteristics (myeloid neoplasias only) as well as outcome. Furthermore, we will register the clinical, biological, and cytogenetic characteristics of the acute lymphoblastic leukemia as well as type of treatment given.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ALL diagnosed 1980-2007 | Cases of childhood acute lymphoblastic leukemia (ALL) diagnosed between 1980 and 2007 and included in the clinical trials of the participating ALL study groups |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Pattern of SMN subtypes | Pattern of the main groups of SMN and their clinical charactiristics | At 20 years from diagnosis |
| Overall survival by subtype | Overall survival by the main SMN subtypes (myeloid malignancies, brain tumors, lymphomas, sarcomas, carcinomas, others) | At 10 years from diagnosis of SMN |
| Risk factors for development of SMN | Identification of risk factors linked to the interval to SMN, the subtype of SMN, and the survival after. These risk factors are clinical characteristics of ALL or the anti-ALL therapy administered | At 20 years from ALL diagnosis |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
The study cohort includes all registered cases of second cancers occurring as the first event among children diagnosed with acute lymphoblastic leukemia and treated according to protocol by one of the collaborative groups participating in the present study
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kjeld Schmiegelow, M.D. | Rigshospitalet, Denmark | Principal Investigator |
| Maria G Valsecchi, M.Sci, | Dipartimento di medicina clinica e prevenzione, University of Milan, Italy | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kjeld Schmiegelow | Copenhagen | 2100 | Denmark |
Not provided
| ID | Term |
|---|---|
| D054198 | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
| D016609 | Neoplasms, Second Primary |
| ID | Term |
|---|---|
| D007945 | Leukemia, Lymphoid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
| ALL-BFM Study Group |
| NETWORK |
| Dutch Childhood Oncology Group | OTHER |
| St. Jude Children's Research Hospital | OTHER |
| United Kingdom Children's Cancer Study Group | OTHER |
Not provided
Not provided
Not provided
| D006402 |
| Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |